Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Novartis trial marks ResearchKit first in MS

ElevateMS study will allow participants to contribute from smartphones

Novartis MS smartphone Apple iPhone ResearchKit study

Novartis has launched the first large-scale research study in multiple sclerosis using Apple’s ResearchKit software.

Participants will be able to contribute directly from their smartphones, via sensors that will collect movement and symptom data, removing the need for clinic visits.

The US mobile-enabled study uses a free-to-download iPhone app that was built on Apple’s ResearchKit platform, software that’s already in use at companies such as GlaxoSmithKline and Celgene.

Novartis’ Evaluation of Evidence from Smart Phone Sensors and Patient-Reported Outcomes in Participants with Multiple Sclerosis, or elevateMS, study aims to improve understanding of patients’ daily challenges.

The Swiss pharma firm and its tech partner Sage Biosystems also hope real-time data collection will enable them to uncover new potential measurements of treatment effectiveness.

Stanley Cohan, medical director at Providence Multiple Sclerosis Center in Portland, Oregon, is a scientific advisor to the study.

He said: “As physicians, we always want to know how our patients with MS are doing on the treatments we prescribe.

“With the elevateMS app, study participants can frequently document their symptoms in a personal health story. In turn, this data may provide researchers with new ways to look at disease progression and treatment effectiveness.”

The elevateMS mobile app can be downloaded from the Apple App Store and offers users a range of activities, including brainteasers and questionnaires about their health, while taking measures from the iPhone’s built-in sensors.

The study is only open to adults in the US that own an iPhone (4s or newer model), but participants with and without MS can sign up to help researchers better understand what it’s like to live with the condition.

22nd August 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Cell and gene therapy
Tackling the manufacturing cost and complexity challenges...

Infographics